to identify factors affecting the efficacy of indomethacin in closing symptomatic patent ductus arteriosus ( pda ) , we studied the pharmacokinetics of intravenous indomethacin , 0.2 mg per kilogram of body weight , in 35 premature infants with symptomatic pda .
C0021246
indomethacin
C0013274
pda